Metabolomic Profiling of Adults with Congenital Heart Disease

• Main Authors: Ari Cedars, Cedric Manlhiot, Jong-Mi Ko, Teodoro Bottiglieri, Erland Arning, Angela Weingarten, Alexander Opotowsky, Shelby Kutty
• Format: Article
• Language: English
• Published: MDPI AG 2021-08-01
• Series: Metabolites
• Subjects: adult congenital heart disease; metabolomic analysis; biomarkers
• Online Access: https://www.mdpi.com/2218-1989/11/8/525

Metabolomic analysis may provide an integrated assessment in genetically and pathologically heterogeneous populations. We used metabolomic analysis to gain mechanistic insight into the small and diverse population of adults with congenital heart disease (ACHD). Consecutive ACHD patients seen at a single institution were enrolled. Clinical variables and whole blood were collected at regular clinical visits. Stored plasma samples were analyzed for the concentrations of 674 metabolites and metabolic markers using mass spectrometry with internal standards. These samples were compared to 28 simultaneously assessed healthy non-ACHD controls. Principal component analysis and multivariable regression modeling were used to identify metabolites associated with clinical outcomes in ACHD. Plasma from ACHD and healthy control patients differed in the concentrations of multiple metabolites. Differences between control and ACHD were greater in number and in degree than those between ACHD anatomic groups. A metabolite cluster containing amino acids and metabolites of amino acids correlated with negative clinical outcomes across all anatomic groups. Metabolites in the arginine metabolic pathway, betaine, dehydroepiandrosterone, cystine, 1-methylhistidine, serotonin and bile acids were associated with specific clinical outcomes. Metabolic markers of disease may both be useful as biomarkers for disease activity and suggest etiologically related pathways as possible targets for disease-modifying intervention.